Search results
Showing 991 to 1005 of 2581 results for methods
NICE has developed a medtech innovation briefing (MIB) on Biopatch for venous or arterial catheter sites .
In development Reference number: GID-HTE10070 Expected publication date: TBC
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)
Evidence-based recommendations on pralsetinib (Gavreto) for treating RET fusion-positive advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on brigatinib (Alunbrig) for anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor.
Evidence-based recommendations on abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer in adults.
Laparoscopic helium plasma coagulation for the treatment of endometriosis (HTG112)
Evidence-based recommendations on laparoscopic helium plasma coagulation for the treatment of endometriosis. This involves a minimally invasive procedure used to vaporise endometrial deposits.
View recommendations for HTG112Show all sections
Sections for HTG112
Biographies and registered interests for members of the Technology Appraisal Committee C
Biographies and registered interests for members of the Technology Appraisal Committee C
This quality standard covers renal replacement therapy services for adults with kidney failure. It includes treatment options, such as dialysis and kidney transplant. It describes high-quality care in priority areas for improvement.
View quality statements for QS72Show all sections
Sections for QS72
- Quality statements
- Quality statement 1: Education programmes
- Quality statement 2: Transplantation – pre-emptive
- Quality statement 3: Transplantation – on dialysis
- Quality statement 4: Dialysis access preparation
- Quality statement 5: Home-based dialysis
- Quality statement 6: Patient transport
- Quality statement 7: Transplantation – rapid access to a specialist histopathology service
Violent and aggressive behaviours in people with mental health problems (QS154)
This quality standard covers short-term prevention and management of violent and physically threatening behaviour among adults, children and young people with a mental health problem. It applies to settings where mental health, health and social care services are provided. This includes community settings and care received at home. It describes high-quality care in priority areas for improvement.
View quality statements for QS154Show all sections
Sections for QS154
- Quality statements
- Quality statement 1: Identifying triggers and warning signs
- Quality statement 2: Preventing and managing violent or aggressive behaviour
- Quality statement 3: Physical health during and after manual restraint
- Quality statement 4: Physical health after rapid tranquillisation
- Quality statement 5: Immediate post-incident debrief
- About this quality standard
Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (HTG333)
Evidence-based recommendations on electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma. This involves injecting a chemotherapy drug into the tumour and using electrical pulses to increase its effect.
Anaphylaxis: assessment and referral after emergency treatment (CG134)
This guideline covers assessment and referral for anaphylaxis. It aims to improve the quality of care for people with suspected anaphylaxis by detailing the assessments that are needed and recommending referral to specialist allergy services.
is considered to be adequate for the majority of pressure ulcers, other methods, including mechanical, enzymatic, sharp debridement and...
patients undergoing focal cryoablation (including details of case selection, methods of follow-up and outcomes) for local audit....
This guideline covers managing and monitoring diabetic retinopathy in people under the care of hospital eye services. This includes non-proliferative and proliferative diabetic retinopathy, and diabetic macular oedema.